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Abstract
Background—Data on the association between subclinical thyroid dysfunction and fractures 
conflict.
Purpose—To assess the risk for hip and nonspine fractures associated with subclinical thyroid 
dysfunction among prospective cohorts.
Data Sources—Search of MEDLINE and EMBASE (1946 to 16 March 2014) and reference 
lists of retrieved articles without language restriction.
Study Selection—Two physicians screened and identified prospective cohorts that measured 
thyroid function and followed participants to assess fracture outcomes.
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Data Extraction—One reviewer extracted data using a standardized protocol, and another 
verified data. Both reviewers independently assessed methodological quality of the studies.
Data Synthesis—The 7 population-based cohorts of heterogeneous quality included 50 245 
participants with 1966 hip and 3281 nonspine fractures. In random-effects models that included 
the 5 higher-quality studies, the pooled adjusted hazard ratios (HRs) of participants with 
subclinical hyperthyroidism versus euthyrodism were 1.38 (95% CI, 0.92 to 2.07) for hip fractures 
and 1.20 (CI, 0.83 to 1.72) for nonspine fractures without statistical heterogeneity (P = 0.82 and 
0.52, respectively; I2 = 0%). Pooled estimates for the 7 cohorts were 1.26 (CI, 0.96 to 1.65) for hip 
fractures and 1.16 (CI, 0.95 to 1.42) for nonspine fractures. When thyroxine recipients were 
excluded, the HRs for participants with subclinical hyperthyroidism were 2.16 (CI, 0.87 to 5.37) 
for hip fractures and 1.43 (CI, 0.73 to 2.78) for nonspine fractures. For participants with 
subclinical hypothyroidism, HRs from higher-quality studies were 1.12 (CI, 0.83 to 1.51) for hip 
fractures and 1.04 (CI, 0.76 to 1.42) for nonspine fractures (P for heterogeneity = 0.69 and 0.88, 
respectively; I2 = 0%).
Limitations—Selective reporting cannot be excluded. Adjustment for potential common 
confounders varied and was not adequately done across all studies.
Conclusion—Subclinical hyperthyroidism might be associated with an increased risk for hip and 
nonspine fractures, but additional large, high-quality studies are needed.
Primary Funding Source—Swiss National Science Foundation.
About 10% of women and 3% of men older than 60 years have subclinical hypothyroidism 
(1-3), and prevalence increases with age. Subclinical hypothyroidism is defined as elevated 
thyroid-stimulating hormone (TSH) and normal free thyroxine (FT4) levels (4). Subclinical 
hyperthyroidism, defined as decreased TSH and normal FT4 and triiodothyronine (T3) levels 
(4), is less common and affects about 1.5% of women and 1% of men older than 60 years. 
Subclinical thyroid dysfunction has previously been associated with an increased risk for 
coronary heart disease and heart failure events (5-7).
Thyroid hormones influence the homeostasis and remodeling of bone (8). Overt 
hyperthyroidism is a risk factor for fractures (9). A few observational studies have also 
found an increased risk for fracture in persons with overt hypothyroidism (10, 11).
The association between subclinical thyroid dysfunction and fractures remains unclear. A 
prospective cohort study of 3567 elderly participants found an increased risk for hip 
fractures in men with endogenous subclinical hyperthyroidism and a similar trend in women, 
whereas subclinical hypothyroidism was associated with an increased risk for hip fracture in 
men only (12). Conversely, a case–cohort study of 1526 ambulatory men older than 65 years 
found no significant relationship between subclinical hyperthyroidism and fractures, but 
low-normal TSH levels were significantly associated with an increased risk for hip fractures 
(13). Other prospective studies (14) did not adjust for common relevant potential 
confounders between subclinical thyroid dysfunction and fractures, such as age, sex, body 
mass index, smoking, and corticosteroid use (15-24). Two meta-analyses of postmenopausal 
women with exogenous subclinical hyperthyroidism due to thyroxine substitution showed a 
reduction in bone mineral density (BMD), which is a surrogate marker for osteoporosis (25, 
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26). To our knowledge, no meta-analysis has been done on the risk for fractures related with 
subclinical thyroid dysfunction. Therefore, we did a meta-analysis to determine whether 
subclinical thyroid dysfunction and TSH levels were associated with an increased risk for 
fractures in prospective cohort studies.
Methods
Data Sources and Searches
We followed a standardized protocol to do this meta-analysis. Similar to our previous study 
(27), we conducted a systematic literature search for articles in any language on the 
association between subclinical thyroid dysfunction (both subclinical hypothyroidism and 
hyperthyroidism) and fractures published between 1946 and 16 March 2014 in the 
MEDLINE and EMBASE databases. In Ovid MEDLINE, we used the following broadly 
defined Medical Subject Headings: thyroid diseases, hypothyroidism, hyperthyroidism, 
thyroid hormones, thyrotropin, subclinical hyperthyroidism, subclinical hypothyroidism, 
subclinical dysthyroidism, subclinical thyroid, and fractures or osteoporosis. These headings 
were combined with the filter designed by British Medical Journal knowledge information 
specialists to identify randomized, controlled trials; cohorts; and case–control studies 
without year limitation or exclusion of comments, editorials, meta-analyses, practice 
guidelines, reviews, letters, journal correspondences, books, conference papers, or animal 
studies (28). We used a similar procedure in EMBASE. We also searched the bibliographies 
of key articles in the field and those included in this review, and we contacted authors for 
unpublished studies.
Study Selection
Similar to our previous study (27), 2 authors independently screened the abstracts and titles 
of the search results and retained articles on prospective cohorts studying the association 
between thyroid dysfunction and osteoporotic fractures. The same reviewers independently 
assessed the remaining full-text articles for eligibility on the basis of predefined criteria. 
Any disagreement was resolved by discussion with a third author. Because some prospective 
studies that measured thyroid function and assessed multiple outcomes may not have 
reported fracture outcomes in the abstract, we also assessed the full text and tables for 
reported fracture data in these studies. We included only studies that fulfilled the following a 
priori–defined criteria: measurement of thyroid function, prospective follow-up of 
participants, assessment of fracture outcomes, comparison group with euthyroidism, and 
provision of hazard ratios (HRs) or sufficient data to calculate them. We excluded studies 
that examined only persons with a history of overt thyroid dysfunction or thyroid cancer.
We considered nonspine, hip, and any fractures, but we excluded spine fractures because 
vertebral fracture age is difficult to assess without serial radiographs and the accuracy of 
self-report is poor (29).
Agreement among reviewers was 97.9% for the first screening of titles and abstracts (κ = 
0.69) and 100% for full-text screening (κ = 1.0).
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Data Extraction and Quality Assessment
We used a standardized data abstraction form to extract information about participant 
characteristics, the criteria used to define subclinical thyroid dysfunction, and fractures. We 
evaluated study quality using slightly up-dated criteria (27, 30), adding inclusion of testing 
for the assumption of proportional hazards. One physician reviewer extracted data, and 
another checked data. We assessed key indicators for the quality of the cohort studies (31, 
32): the population studied (convenience sample vs. population-based, which was defined as 
a random sample of the general population) and methods of fracture ascertainment and 
adjudication (considered adequate if done by an expert panel blinded to thyroid status using 
a clear out-come definition); assessment of the proportional hazard assumption; 
completeness of follow-up; and adjustment for potential confounders. We defined age, sex, 
body mass index, smoking, and corticosteroid use (15-24) as common relevant potential 
confounders for the relationship between subclinical thyroid dysfunction and fractures based 
on a literature search considering their prevalence and strength of association with fractures 
and thyroid dysfunction. We required adjustment for most of these risk factors and lack of 
violation of the proportional hazard assumption for a study to be rated as higher quality. If 
an article did not clearly mention one of these criteria, we considered that it had not been 
done. Two reviewers independently rated all studies for quality, and disagreement was 
resolved with a third reviewer.
We contacted the authors of all cohorts to request more detailed data on the association 
between subclinical thyroid dysfunction and fractures. We used the most adjusted HRs and 
95% CIs available.
Data Synthesis and Statistical Analysis
We used TSH cutoff levels as reported by each cohort. If not otherwise specified by a 
cohort, we used a common definition of subclinical thyroid disease based on expert reviews 
(4, 33) and the definition used in the Cardiovascular Health Study (12, 34), as done in 
previous articles (5-7). Subclinical hypothyroidism was defined as a TSH level greater than 
4.5 to 20.0 mIU/L and an FT4 level in the reference range. Subclinical hyperthyroidism was 
defined as a TSH level less than 0.45 mIU/L and an FT4 level in the reference range. 
Euthyroidism was defined as a TSH cutoff level from 0.45 to 4.5 mIU/L. For FT4, we used 
study-specific cutoff levels because these measurements show greater intermethod variation 
than TSH. Three studies (14, 35, 36) did not include FT4 in their definition of subclinical 
thyroid dysfunction. Two of these studies (35, 36) were included in the main analysis of the 
higher-quality studies, but we did a sensitivity analysis excluding studies without FT4 
measurement or with abnormal FT4 because some participants may have overt thyroid 
dysfunction. Two of these studies differentiated between low and suppressed TSH levels 
(14, 35). We used data from the group with low but not suppressed TSH levels because, 
according to unpublished data in our previous individual-participant data analysis (7), about 
one fourth of persons with a TSH level less than 0.1 mIU/L had overt hyperthyroidism, but 
only about 5% of those with a TSH level greater than 0.1 mIU/L had overt hyperthyroidism.
We qualitatively synthesized data and assessed which participants were included, the 
definition of thyroid dysfunction, and which types of fractures were studied. First, for the 
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higher-quality studies, we calculated pooled estimates and 95% CIs of the risk for 
subclinical hyperthyroidism and hypothyroidism on hip and nonspine fractures using 
random-effects models based on the Knapp–Hartung approach (37) to account for the 
uncertainty associated with statistical heterogeneity (tau-square estimation) and the small 
number of studies included (38). Second, we assessed overall pooled estimates for all studies 
using the same approach. Because the Cardiovascular Health Study only reported estimates 
stratified by sex, we used fixed effects to combine these estimates before pooling them with 
other cohorts (12).
To assess heterogeneity among studies, we quantified the Q statistic with a conservative P 
value of 0.10 (39) and used the I2 statistic, which describes the total variation across studies 
attributable to heterogeneity rather than chance (I2 > 50%, indicating at least moderate 
statistical heterogeneity) (40). To explore sources of heterogeneity, we did several 
predefined sensitivity analyses from all included studies using random-effects models. We 
also did analyses stratified by age and sex. Stratified analysis were accompanied by 
interaction tests based on Z scores, which are defined as the difference in effect estimates 
between strata divided by the SE of the difference.
We used an adjusted rank correlation test to assess for publication bias (41). However, 
graphical and statistical methods may not be reliable because of their limited power due to 
the small number of studies included in our meta-analysis (42). All analyses were done by 
using Stata, version 12.1 (StataCorp, College Station, Texas).
Role of the Funding Source
The funding source had no role in defining questions, abstracting data, synthesizing results, 
or preparing or deciding to submit the manuscript for publication.
RESULTS
Study Selection
Of the 1185 reports initially identified, 1132 were excluded on the basis of their title and 
abstract because they were unrelated to the association between subclinical thyroid 
dysfunction and fractures or were not prospective studies with measurement of thyroid 
hormones (Appendix Figure 1, available at www.annals.org). After full-text review of the 53 
selected articles, we excluded 46 studies that did not meet the inclusion criteria (Appendix 
Table, available at www.annals.org). Seven studies met all eligibility criteria and were 
included in the analyses.
Study Characteristics
Table 1 shows the study characteristics of included studies in our meta-analysis and the HRs 
for the associations between subclinical thyroid dysfunction and hip and nonspine fractures. 
These 7 studies included 50 245 participants with 1966 hip and 3281 nonspine fractures. 
Four cohorts included men and women, 2 cohorts included only women, and 1 cohort 
included only men. Follow-up ranged from 3.7 to 13 years. One cohort included only 
participants treated with thyroid hormone, and 2 cohorts excluded all treated participants. 
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Most cohorts assessed subclinical hyperthyroidism and hypothyroidism, and 1 cohort 
assessed only subclinical hyperthyroidism. All studies used a second- or third-generation 
TSH assay.
Description of Study Quality
The quality of included studies was heterogeneous. All studies were population-based 
(Table 2). Four used a formal adjudication procedure for fracture ascertainment, and 3 
reported adjudication of fractures without knowledge of thyroid status. Five cohorts 
provided information on loss to follow-up, which was 2% or less. All cohorts reported 
nonviolation of the proportional hazard assumption. Table 2 indicates the confounders that 
were adjusted for by the different studies by using appropriate multivariate analyses. Five of 
the studies reported HRs with adjustment for most of the aforementioned common relevant 
confounders, but 2 studies lacked such adjustment (14, 46). On the basis of the quality 
assessment in Table 2, with the request of the adjustment for most of these confounders and 
lack of violation of the proportional hazard assumption, 5 studies were rated higher quality 
and thus were included in the main pooled analysis (12, 13, 35, 36, 44).
Subclinical Hyperthyroidism and Hip Fractures
All studies found an increased risk for hip fractures associated with subclinical 
hyperthyroidism, and the Sheffield cohort had a statistically significant increased risk 
(Figure, top) (46). Among the higher-quality studies, 3 studies showed an HR greater than 
1.5; the 2 largest studies found a lower HR, although TEARS (Thyroid Epidemiology Audit 
and Research Study) was not included in the analysis of the higher-quality studies because 
of inadequate adjustment for common relevant confounders and enrollment of only 
participants receiving long-term thyroxine medication. In a random-effects model with the 5 
higher-quality studies, the pooled HR of subclinical hyperthyroidism and hip fractures was 
1.38 (95% CI, 0.92 to 2.07) without evidence of heterogeneity (P for heterogeneity = 0.82; 
I2 = 0%) (Table 3). Pooling estimates from all 7 included studies yielded similar results 
(Table 3). Including only studies that used a TSH cutoff level less than 0.45 mIU/L yielded 
an HR of 1.46 (CI, 0.62 to 3.45) for hip fractures. Pooled estimates for a TSH cutoff level of 
0.1 mIU/L or less yielded an HR of 2.03 (CI, 0.27 to 15.00) with large CIs because only 2 
studies reported such data. Results excluding all thyroid hormone recipients and thereby 
limiting the analysis to participants with endogenous subclinical hyperthyroidism indicated 
an increased risk for hip fracture (HR, 2.16 [CI, 0.87 to 5.37]). Pre-defined sensitivity 
analyses excluding studies that did not include FT4 in their definition of subclinical thyroid 
dysfunction, with the potential enrollment of participants with overt thyroid disease, yielded 
a slightly higher fracture risk. Stratified analyses by sex and age did not show statistical 
significance for interaction. A sensitivity analysis considering our predefined quality 
measures showed similar results for inclusion of studies using formal adjudication 
procedures. Results remained similar after excluding 1 study with a case–cohort design. 
After excluding a study that lacked FT4 measurements, included only thyroxine-treated 
patients, and therefore compared overtreated participants with those in whom euthyroidism 
was achieved (14), the HR for hip fractures was 1.43 (CI, 0.99 to 2.06) and the duration of 
overtreatment was not reported.
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Subclinical Hyperthyroidism and Nonspine Fractures
All included studies had a pattern of an increased risk for nonspine fractures associated with 
subclinical hyperthyroidism, although it was not statistically significant (Figure, bottom). 
The pooled HR, including estimates from the 4 higher-quality studies, was 1.20 (CI, 0.83 to 
1.72), with weak evidence for statistical heterogeneity (P for heterogeneity = 0.52; I2 = 0%). 
Pooling estimates from all studies and sensitivity analyses yielded similar results (Table 3) 
to those for the association between subclinical hyperthyroidism and hip fractures.
Subclinical Hypothyroidism and Fractures
Most individual studies showed a statistically non significant pattern of an increased risk for 
hip fractures associated with subclinical hypothyroidism (Appendix Figure 2, available at 
www.annals.org). Pooled HRs from the higher-quality studies were 1.12 (CI, 0.83 to 1.51) 
for hip fractures and 1.04 (CI, 0.76 to 1.42) for nonspine fractures, both without evidence for 
heterogeneity across studies (P = 0.69 and 0.88, respectively; I2 0%) (Appendix Figure 2 
and Table 4). Pooled estimates from studies with FT4 measurements, which have excluded 
possibly enrolled participants with overt hypothyroidism, as well as from studies excluding 
thyroxine recipients, yielded similar results.
Evaluation of Potential Publication Bias
The rank correlation tests indicated little evidence of publication bias (P > 0.05) for all 
associations, although these tests are not sensitive due to the small number of studies (42).
DISCUSSION
In this meta-analysis of 7 population-based, prospective cohort studies, pooled results from 
the 5 higher-quality studies indicated that subclinical hyperthyroidism might be associated 
with an increased risk for hip fractures (HR, 1.38 [CI, 0.92 to 2.07]) and nonspine fractures 
(HR, 1.20 [CI, 0.83 to 1.72]). When thyroxine recipients were excluded, the HRs for 
participants with subclinical hyperthyroidism were 2.16 (CI, 0.87 to 5.37) for hip fractures 
and 1.43 (CI, 0.73 to 2.78) for nonspine fractures. The relationship between subclinical 
hyperthyroidism and fractures seemed to be stronger among adults with a TSH cutoff level 
of 0.1 mIU/L or less, which indicated a possible dose– response relationship; however, CIs 
were large because only 2 studies provided such data. In subclinical hypothyroidism, the risk 
for fractures did not seem to be increased among the higher-quality studies.
To our knowledge, our study is the first systematic review and meta-analysis to examine the 
association between subclinical thyroid dysfunction and fracture risk. Our findings are 
supported by 2 previous meta-analyses of TSH-suppressive thyroxine therapy (25, 26), 
which found that in postmenopausal women, exogenous subclinical hyperthyroidism was 
significantly associated with a 0.91% annual decrease in bone mass (25). In addition, 
interventional studies on endogenous subclinical hyperthyroidism due to nodular goiter 
showed a 2% annual lower BMD than in postmenopausal women treated with an antithyroid 
drug or radioiodine (47, 48). In overt hyperthyroidism, a meta-analysis of 5 cohort or case–
control studies showed that the risk for fractures normalized after 1 year of antithyroid 
therapy (9). A recent systematic review on the clinical consequences of variations in thyroid 
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hormones within the euthyroid reference range found good evidence for increased fracture 
risk associated with lower euthyroid TSH levels (49).
Different hypotheses have been made about the mechanisms of the association between 
subclinical hyperthyroidism and fractures. Subclinical hyperthyroidism has been associated 
with decreased BMD (25, 26) and may contribute to osteoporosis (50), which increases 
vulnerability to fractures (51). A study showed that thigh muscle strength decreases in 
subclinical hyperthyroidism and possibly leads to an increased risk for fall-related fractures 
(52, 53), although data on a direct association between subclinical hyperthyroidism and falls 
are lacking. The duration of subclinical hyperthyroidism may also play an important role in 
fracture development (47, 48, 51); however, this is difficult to assess, especially for 
endogenous subclinical hyperthyroidism (54). The observed lower risk for fractures when 
combining patients with exogenous and endogenous subclinical hyperthyroidism may be 
due to a presumably lower risk for fractures in patients with exogenous subclinical 
hyperthyroidism who may receive a reduced dosing of thyroid hormones, which limits the 
duration of the dysfunction. We found no evidence of a risk difference for fractures in 
women compared with men, despite the fact that women—especially postmenopausal 
women—have an increased risk for osteoporosis. In Americans aged 80 years, the 10-year 
probability of a hip fracture was 14% for women and 6% for men (55). Because all studies 
but 1 (35) did not have HRs adjusted for BMD, our analysis did not include BMD. When the 
Study of Osteoporotic Fractures (35) accounted for BMD, results did not substantially 
change the association between subclinical hyperthyroidism and fractures. However, the 
extent to which bone mass mediates the adverse effect of low TSH levels on fracture risk 
remains uncertain.
Prospective data on the association between subclinical hypothyroidism and fractures are 
scarce, and studies mainly investigate treated patients. A small randomized study showed a 
1.3% reduction in lumbar BMD after 48 weeks of thyroxine treatment for subclinical 
hypothyroidism compared with placebo (56), and a large registry study in Denmark found 
an increased fracture risk for participants with overt hypothyroidism up to 4 years after 
initiation of thyroxine substitution (57). In our meta-analysis, we did not find an increased 
risk for fractures among participants with subclinical hypothyroidism. However, insufficient 
data prevented us from doing a sensitivity analysis to assess fracture risk among participants 
with subclinical hypothyroidism receiving thyroxine (compared with un-treated 
participants). Overall, we did not find an effect of subclinical hypothyroidism on fractures, 
but the actual effect of thyroxine therapy on subclinical hypothyroidism cannot be assessed 
with the present study data.
Our meta-analysis of subclinical thyroid dysfunction and fractures has important strengths. 
First, by pooling the data of all available studies, we analyzed a total of 1966 hip and 3281 
nonspine fractures in more than 50 000 participants, which increased power to detect an 
association (58). Second, only population-based prospective studies were included. Third, 
by contacting all principal investigators or coauthors of these 7 studies, we received 
additional data that allowed us to derive more uniform subgroup and sensitivity analyses.
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Our study also has limitations. First, because it is a meta-analysis of observational studies, 
results have to be interpreted with caution, and potential biases, confounding, and 
heterogeneity must be carefully investigated (31, 59). The quality of the studies was 
heterogeneous. Some studies did not adequately adjust for all common potential 
confounders, which left a risk for residual confounding, and loss to follow-up and missing 
data were not reported in all studies. To address these limitations, we reported this study 
according to accepted guidelines for a meta-analysis of observational studies and did 
sensitivity analyses when appropriate (59). Furthermore, we excluded studies with major 
limitations from our main analysis and pooled only the 5 higher-quality studies. Second, 
selection bias may be present. To reduce this possibility, we used broad inclusion criteria 
and did sensitivity analyses stratified by design characteristics (59). Third, selective 
reporting cannot be excluded because tests and graphical assessment for publication bias are 
not sensitive enough owing to the small number of studies included in our meta-analysis 
(42). Fourth, our analysis included only European or U.S. cohorts, which limits the 
generalizability to other settings. Fifth, 6 of the 7 studies measured thyroid function at 
baseline only. Abnormal TSH levels can spontaneously normalize in 20% to 40% of persons 
after a mean follow-up of 2 to 4 years (60, 61), which may have decreased the potential 
associations. Sixth, only 4 of the 7 cohorts included the FT4 level and no study included the 
T3 level in its definition of subclinical thyroid disease. However, excluding studies (14, 35, 
36) in a sensitivity analysis that did not include the FT4 level yielded similar results with 
slightly higher point estimates. Finally, we conducted analyses stratified by age and sex 
using aggregate data at study level, but we might have missed a significant relationship 
because of ecological bias (62).
What are the clinical and research implications of these findings? Recent guidelines 
recommend treatment of subclinical hyperthyroidism in all persons older than 65 years (63), 
and our findings of a possibly increased fracture risk associated with subclinical 
hyperthyroidism are consistent with these guidelines, although there are no studies in which 
treatment resulted in a reduced fracture risk. Given the high prevalence of both osteoporosis 
and subclinical thyroid dysfunction in our aging populations, our findings may have public 
health implications. However, because this is a meta-analysis of observational studies, we 
cannot rule out that our findings are due to reasons other than subclinical thyroid 
dysfunction. A meta-analysis of individual-participant data that does not have potential 
aggregation bias could provide more insight through uniform TSH cutoff levels, 
standardized adjustment for potential confounding factors, and a thorough analysis of 
subgroups. To prove causality, large randomized, controlled trials are necessary to assess the 
efficacy of normalizing TSH levels in subclinical thyroid dysfunction associated with 
fracture risk (64). For subclinical hyperthyroidism, its low prevalence and the requirement 
for long follow-up make such trials a challenge. But for subclinical hypothyroidism, the 
ongoing TRUST (Thyroid Hormone Replacement for Subclinical Hypothyroidism) trial 
(ClinicalTrials.gov: NCT01660126) will clarify this issue (65).
In summary, our systematic review indicates that subclinical hyperthyroidism might be 
associated with an increased risk for hip and nonspine fractures, but additional large, high-
quality studies are needed.
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Appenedix
Appendix Figure 1. Summary of evidence search and selection
Studies evaluated for inclusion in the meta-analysis (adapted from PRISMA Statement flow 
diagram [43]).
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† From key articles in the field and contact with the authors (44).
‡ Exclusion criteria included records unrelated to the association between subclinical thyroid 
dysfunction and fractures or studies without prospective design and thyroid measurement.
§ For list of excluded full-text articles, see the Appendix Table (available at 
www.annals.org).
Appendix Table
Studies Excluded After Full-Text Screening
Reason for Exclusion References
Review, meeting 
abstract,
 poster, or editorial
Aloumanis K, Eastell R, McCloskey EV. The effect of a history of thyroid disease in 
skeletal and muscle health and the risk of fractures in elderly women. Eur J Clin Invest. 
2009;39:3.
Compston JE. Thyroid hormone therapy and the skeleton. Clin Endocrinol (Oxf). 
1993;39:519-20.
Faber J, Galløe AM. Changes in bone mass during prolonged subclinical hyperthyroidism 
due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol. 1994;130:350-6. [PMID: 
8162163]
Lindstedt G, Nyström E. [Increased risk of bone-fragility-related fractures in TSH–
suppressive thyroxine treatment]. Lakartidningen. 2002;99:2844-5. [PMID: 12143138]
Herrick B. Subclinical hypothyroidism. Am Fam Physician. 2008;77:953-5.
No thyroid function test Bach-Mortensen P, Hyldstrup L, Appleyard M, Hindsø K, Gebuhr P, Sonne-Holm S. 
Digital x-ray radiogrammetry identifies women at risk of osteoporotic fracture: results 
from a prospective study. Calcif Tissue Int. 2006;79:1-6. [PMID: 16868669]
Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk factors 
for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl 
J Med. 1995;332:767-73. [PMID: 7862179]
Huopio J, Honkanen R, Jurvelin J, Saarikoski S, Alhava E, Kröger H. Role of chronic 
health disorders in perimenopausal fractures. Osteoporos Int. 2005;16:1404-11. [PMID: 
15739033]
Ahmed LA, Schirmer H, Berntsen GK, Fønnebø V, Joakimsen RM. Self-reported diseases 
and the risk of non-vertebral fractures: the Tromsø study. Osteoporos Int. 2006;17:46-53. 
[PMID: 15838716]
Turner MR, Camacho X, Fischer HD, Austin PC, Anderson GM, Rochon PA, et al. 
Levothyroxine dose and risk of fractures in older adults: nested case-control study. BMJ. 
2011;342:d2238. [PMID: 21527461]
Ko YJ, Kim JY, Lee J, Song HJ, Kim JY, Choi NK, et al. Levothyroxine dose and fracture 
risk according to the osteoporosis status in elderly women. J Prev Med Public Health. 
2014;47:36-46. [PMID: 24570805]
Nguyen TT, Heath H 3rd, Bryant SC, O’Fallon WM, Melton LJ 3rd. Fractures after 
thyroidectomy in men: a population-based cohort
study. J Bone Miner Res. 1997;12:1092-9. [PMID: 9200009]
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Reported the same study
 already selected
 without additional
 data to extract
Flynn RWV, Bonellie S, MacDonald TM, Leese GP. Increased risk of osteoporotic 
fracture in the thyroid population. Pharmacoepidemiology and Drug Safety. 2011;20:S29-
S30.
Hofman A, Breteler MM, van Duijn CM, Krestin GP, Pols HA, Stricker BH, et al. The 
Rotterdam Study: objectives and design update. Eur J Epidemiol. 2007;22:819-29. [PMID: 
17955331]
Lee JS, Buzkova P, Fink H, Vu J, Carbone L, Bauer D, et al. Subclinical thyroid 
dysfunction and incident hip fracture in older adults. Clinical and Translational Science. 
2010;3:S11.
Leese G, Flynn R. Is it safe for patients taking thyroxine to have a low but not suppressed 
serum TSH concentration? Endocrine
Abstracts. 2010;21:OC5.6.
Barrett-Connor E, Nielson CM, Orwoll E, Bauer DC, Cauley JA; Osteoporotic Fractures in 
Men Study Group. Epidemiology of rib fractures in older men: Osteoporotic Fractures in 
Men (MrOS) prospective cohort study. BMJ. 2010;340:c1069. [PMID: 20231246]
Garin MC, Arnold AM, Lee JS, Robbins JA, Cappola AR. Subclinical thyroid dysfunction 
is not associated with hip fracture or lower bone mineral density in older adults. Endocrine 
Reviews. 2012;33.
Bauer DC, Nevitt MC, Ettinger B, Stone K. Low thyrotropin levels are not associated with 
bone loss in older women: a prospective study. J Clin Endocrinol Metab. 1997;82:2931-6. 
[PMID: 9284722]
Leese GP, Jung RT, Guthrie C, Waugh N, Browning MC. Morbidity in patients on L-
thyroxine: a comparison of those with a normal
TSH to those with a suppressed TSH. Clin Endocrinol (Oxf). 1992;37:500-3. [PMID: 
1286519]
Only patients with a
 history of 
thyrotoxicosis
Hallengren B, Elmståhl B, Berglund J, Christensen SB, Elmståhl S, Johnell O, et al. No 
increase in fracture incidence in patients treated
for thyrotoxicosis in Malmö during 1970-74. A 20-year population-based follow-up. J 
Intern Med. 1999;246:139-44. [PMID:
10447782]
No fracture outcome Faber J, Jensen IW, Petersen L, Nygaard B, Hegedüs L, Siersbaek-Nielsen K. 
Normalization of serum thyrotrophin by means of
radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in 
postmenopausal women. Clin Endocrinol (Oxf).
1998;48:285-90. [PMID: 9578817]
Appetecchia M. Effects on bone mineral density by treatment of benign nodular goiter with 
mildly suppressive doses of L-thyroxine in a cohort women study. Horm Res. 
2005;64:293-8. [PMID: 16269872]
Buscemi S, Verga S, Cottone S, Andronico G, D’Orio L, Mannino V, et al. Favorable 
clinical heart and bone effects of anti-thyroid drug therapy in endogenous subclinical 
hyperthyroidism. J Endocrinol Invest. 2007;30:230-5. [PMID: 17505157]
Knudsen N, Faber J, Sierbaek-Nielsen A, Vadstrup S, Sørensen HA, Hegedüs L. Thyroid 
hormone treatment aiming at reduced, but
not suppressed, serum thyroid-stimulating hormone levels in nontoxic goitre: effects on 
bone metabolism amongst premenopausal
women. J Intern Med. 1998;243:149-54. [PMID: 9566644]
Lin HC, Yang LY, Kang JH. Increased risk of pulmonary embolism among patients with 
hyperthyroidism: a 5-year follow-up study. J Thromb Haemost. 2010;8:2176-81. [PMID: 
20738759]
Ricken R, Bermpohl F, Schlattmann P, Bschor T, Adli M, Mønter N, et al. Long-term 
treatment with supraphysiological doses of thyroid hormone in affective disorders - effects 
on bone mineral density. J Affect Disord. 2012;136:e89-94. [PMID: 21757236]
Acotto CG, Niepomniszcze H, Vega E, Mautalen CA. Ultrasound parameters and markers 
of bone turnover in hyperthyroidism: a longitudinal study. J Clin Densitom. 2004;7:201-8. 
[PMID: 15181264]
Ceresini G, Morganti S, Rebecchi I, Bertone L, Ceda GP, Bacchi-Modena A, et al. A one-
year follow-up on the effects of raloxifene on thyroid function in postmenopausal women. 
Menopause. 2004;11:176-9. [PMID: 15021447]
Diamond T, Vine J, Smart R, Butler P. Thyrotoxic bone disease in women: a potentially 
reversible disorder. Ann Intern Med. 1994;120:8-11. [PMID: 8250460]
Fujiyama K, Kiriyama T, Ito M, Kimura H, Ashizawa K, Tsuruta M, et al. Suppressive 
doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women. 
Thyroid. 1995;5:13-7. [PMID: 7787427]
Grimnes G, Emaus N, Joakimsen RM, Figenschau Y, Jorde R. The relationship between 
serum TSH and bone mineral density in men and postmenopausal women: the Tromsø 
study. Thyroid. 2008;18:1147-55. [PMID: 18925834]
Gyulai L, Jaggi J, Bauer MS, Younkin S, Rubin L, Attie M, et al. Bone mineral density and 
L-thyroxine treatment in rapidly cycling bipolar disorder. Biol Psychiatry. 1997;41:503-6. 
[PMID: 9034547]
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Limanová Z, Stepán J. [Increased risk of osteoporosis in thyroid hormone substitution 
therapy]. Cas Lek Cesk. 1990;129:625-7.
[PMID: 2354492]
Linde J, Friis T. Osteoporosis in hyperthyroidism estimated by photon absorptiometry. 
Acta Endocrinol (Copenh). 1979;91:437-48.
[PMID: 474036]
Marcocci C, Golia F, Bruno-Bossio G, Vignali E, Pinchera A. Carefully monitored 
levothyroxine suppressive therapy is not associated with bone loss in premenopausal 
women. J Clin Endocrinol Metab. 1994;78:818-23. [PMID: 8157704]
Obermayer-Pietsch B, Dobnig H, Warnkross H, Dimai HP, Weber K, Berghold A, et al. 
Variable bone mass recovery in hyperthyroid bone disease after radioiodine therapy in 
postmenopausal patients. Maturitas. 2000;35:159-66. [PMID: 10924842]
Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B. Accelerated bone loss in hypothyroid 
patients overtreated with L-thyroxine. Ann Intern Med. 1990;113:265-9. [PMID: 2375563]
Stamato FJ, Amarante EC, Furlanetto RP. Effect of combined treatment with calcitonin on 
bone densitometry of patients with treated hypothyroidism. Rev Assoc Med Bras. 
2000;46:177-81. [PMID: 11022359]
Chirico V, Rigoli L, Piraino B, La Rosa M, Salpietro C, Arrigo T. Endocrinopathies in 
beta-thalassemia major: Evidences from ten years of follow-up and evaluation of combined 
iron chelation therapy. Hormone Research in Paediatrics. 2013;80:318.
Legroux-Gérot I, Vignau J, d’Herbomez M, Flipo RM, Cortet B. Predictive factors of 
change in BMD at 1 and 2 years in women with anorexia nervosa: a study of 146 cases. 
Osteoporos Int. 2012;23:2855-61. [PMID: 22349911]
Baldini M, Vigna L, Gallazzi M, Orsatti A, Legnani L, Peracchi G, et al. Age and 
postmenopausal state related risk of axial bone
demineralization in goitrous women treated with L-thyroxine. A longitudinal study. Rivista 
Italiana di Biologia e Medicina.
1996;16:85-90.
La Vignera S, Vicari E, Tumino S, Ciotta L, Condorelli R, Vicari LO, et al. L-thyroxin 
treatment and post-menopausal osteoporosis: relevance of the risk profile present in 
clinical history. Minerva Ginecol. 2008;60:475-84. [PMID: 18981975]
Fowler PB, McIvor J, Sykes L, Macrae KD. The effect of long-term thyroxine on bone 
mineral density and serum cholesterol. J R Coll
Physicians Lond. 1996;30:527-32.
Only risk within the
 euthyroid range
Hoeg A, Gogakos A, Murphy E, Mueller S, Köhrle J, Reid DM, et al. Bone turnover and 
bone mineral density are independently
related to selenium status in healthy euthyroid postmenopausal women. J Clin Endocrinol 
Metab. 2012;97:4061-70. [PMID:
22904175]
Murphy E, Glüer CC, Reid DM, Felsenberg D, Roux C, Eastell R, et al. Thyroid function 
within the upper normal range is associated
with reduced bone mineral density and an increased risk of nonvertebral fractures in 
healthy euthyroid postmenopausal women.
J Clin Endocrinol Metab. 2010;95:3173-81. [PMID: 20410228]
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Appendix Figure 2. Forest plots for subclinical hypothyroidism
CHS = Cardiovascular Health Study; HUNT2 = Nord Trøndelag Health Study 2; MrOS = 
Osteoporotic Fractures in Men Study; NR = not reported; TEARS = Thyroid Epidemiology 
Audit and Research Study. Top. Risk for hip fractures. Bottom. Risk for nonspine fractures.
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Figure. Forest plots for subclinical hyperthyroidism
CHS = Cardiovascular Health Study; HUNT2 = Nord TrØndelag Health Study 2; MrOS = 
Osteoporotic Fractures in Men Study; NR = not reported; SOF = Study of Osteoporotic 
Fractures; TEARS = Thyroid Epidemiology Audit and Research Study. Top. Risk for hip 
fractures. Bottom. Risk for nonspine fractures.
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R
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os
pe
ct
iv
e 
co
ho
rt 
stu
dy
U
ni
te
d 
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ra
l 
pr
ac
tit
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n
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n
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B
M
I =
 b
od
y 
m
as
s i
nd
ex
; C
H
S 
= 
Ca
rd
io
va
sc
ul
ar
 H
ea
lth
 S
tu
dy
; H
U
N
T2
 =
 N
or
d 
Tr
øn
de
la
g 
H
ea
lth
 S
tu
dy
 2
; I
CD
-9
 =
 In
te
rn
at
io
na
l C
la
ss
ifi
ca
tio
n 
of
 D
ise
as
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, N
in
th
 R
ev
isi
on
; I
CD
-1
0 
= 
In
te
rn
at
io
na
l 
Cl
as
sif
ic
at
io
n 
of
 D
ise
as
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, T
en
th
 R
ev
isi
on
; M
rO
S 
= 
O
ste
op
or
ot
ic
 F
ra
ct
ur
es
 in
 M
en
 S
tu
dy
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P 
= 
N
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co
 C
la
ss
ifi
ca
tio
n 
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 S
ur
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ca
l P
ro
ce
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s; 
N
R 
= 
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t r
ep
or
te
d;
 S
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 =
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ird
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n 
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n
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na
l c
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ca
tio
n 
of
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ro
ce
du
re
s; 
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F 
= 
St
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y 
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 O
ste
op
or
ot
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 F
ra
ct
ur
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; T
EA
RS
 =
 T
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ro
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 E
pi
de
m
io
lo
gy
 A
ud
it 
an
d 
Re
se
ar
ch
 S
tu
dy
.
*
If 
an
 a
rti
cl
e 
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d 
no
t c
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ar
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en
tio
n 
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e 
of
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e 
qu
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ea
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s (
e.g
., f
orm
al 
ad
jud
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tio
n p
roc
ed
ure
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dju
dic
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on
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ith
ou
t k
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wl
ed
ge
 of
 th
yro
id 
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tus
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st 
to 
fol
low
-up
, o
r a
dju
stm
en
ts 
ma
de
), w
e 
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n
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er
ed
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at
 it
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ad
 n
ot
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ee
n 
do
ne
.
† A
ll 
stu
di
es
 li
ste
d 
w
er
e 
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pu
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tio
n-
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se
d,
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ch
 w
as
 d
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ed
 a
s a
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nd
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m
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e 
of
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e 
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ne
ra
l p
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ul
at
io
n.
‡ D
ef
in
ed
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s h
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g 
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m
e 
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y 
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r e
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h 
po
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nt
ia
l c
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e.
§ T
he
 sa
m
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e 
w
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 c
ho
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n 
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t t
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 b
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el
in
e 
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t f
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m
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94
 p
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e M
rO
S 
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rt.
∥ C
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m
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 b
y 
th
e 
in
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r.
¶ 2
14
 p
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tic
ip
an
ts 
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.
*
*
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er
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m
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ur
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††
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g 
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al
 p
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‡‡
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at
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m
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 b
y 
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l r
ec
or
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. M
iss
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g 
ou
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e 
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ta
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m
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re
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 h
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ls 
m
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e 
m
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§§
R
ef
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1 
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p 
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e 
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 n
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in
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ur
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 c
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ld
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Table 3
Stratified and Sensitivity Analyses of the Association of Subclinical Hyperthyroidism and 
the Risk for Fractures
Variable Hip Fractures Nonspine Fractures
Pooled HR
(95% CI)
Studies,
n
P
for Heterogeneity*
Pooled HR
(95% CI)
Studies,
n
P for
Heterogeneity*
Higher-quality studies
 Random effects 1.38 (0.92–2.07) 5 0.82 1.20 (0.83–1.72) 4 0.52
 Fixed effects 1.38 (1.04–1.84) 5 1.20 (0.96–1.50) 4
Estimates with all studies
 Random effects 1.26 (0.96–1.65) 7 0.36 1.16 (0.95–1.42) 6 0.67
 Fixed effects 1.22 (1.01–1.47) 7 1.16 (1.00–1.35) 6
Stratified and sensitivity analyses
 Definition of subclinical 
hyperthyroidism
  TSH cutoff level <0.45 mIU/L 1.46 (0.62–3.45) 4 0.128 1.15 (0.75–1.77) 3 0.56
  TSH cutoff level ≤0.1 mIU/L 2.03 (0.27–15.00) 2† 0.51 1.97 (0.36–10.74) 2† 0.94
  Exclusion of recipients of 
thyroxine
2.16 (0.87–5.37) 5 0.067 1.43 (0.73–2.78) 4 0.164
Measurement of FT4 level and 
normal FT4 level
1.90 (0.86–4.21) 4 0.49 1.47 (0.54–3.97) 3 0.87
Stratified by sex‡
  Women 1.22 (0.93–1.74) 6 0.44 1.19 (0.94–1.49) 5 0.63
  Men 1.35 (0.60–3.03) 5 0.38 1.00 (0.44–2.26) 4 0.79
Stratified by mean age at 
enrollment in the cohorts§
  <65 y 1.21 (0.41–3.53) 3 0.140 1.11 (0.78–1.59) 3 0.66
>  ≥65 y 1.67 (0.80–3.45) 4 0.94 1.53 (0.60–3.88) 3 0.78
Characteristics of study quality
 Formal fracture adjudication 
procedures and adjudication
  without knowledge of thyroid 
status
1.31 (0.78–2.19) 4 0.81 1.20 (0.83–1.72) 4 0.52
Studies excluded
 HUNT2 (36), included only hip 
and forearm fractures as nonspine 
fractures
1.40 (0.88–2.21) 6 0.26 1.20 (0.92–1.56) 5 0.58
TEARS (14), included only 
recipients of thyroxine
1.43 (0.99–2.06) 6 0.48 1.22 (0.89–1.66) 5 0.58
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Variable Hip Fractures Nonspine Fractures
Pooled HR
(95% CI)
Studies,
n
P
for Heterogeneity*
Pooled HR
(95% CI)
Studies,
n
P for
Heterogeneity*
SOF (35), used case–cohort design 1.30 (0.90–1.86) 6 0.26 1.14 (0.92–1.42) 5 0.80
FT4 = free thyroxine; HUNT2 = Nord Trøndelag Health Study 2; HR = hazard ratio; SOF = Study of Osteoporotic Fractures; TEARS = Thyroid 
Epidemiology Audit and Research Study; TSH = thyroid-stimulating hormone.
*
P > 0.10; ratios are homogeneous.
†
Did not measure FT4 or triiodothyronine.
‡
P for interaction (sex) = 0.82 (hip fractures) and 0.69 (nonspine fractures).
§
P for interaction (age) = 0.63 (hip fractures) and 0.53 (nonspine fractures).
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Table 4
Stratified and Sensitivity Analyses of the Association of Subclinical Hypothyroidism and 
the Risk for Fractures
Variable Hip Fractures Nonspine Fractures
Pooled HR
(95% CI)
Studies,
n
P for
Heterogeneity*
Pooled HR
(95% CI)
Studies,
n
P for
Heterogeneity*
Higher-quality studies
 Random effects 1.12 (0.83–1.51) 4 0.69 1.04 (0.76–1.42) 3 0.88
 Fixed effects 1.12 (0.93–1.35) 4 1.04 (0.90–1.20) 3
Estimates with all studies
Random effects 1.30 (0.93–1.82) 5 0.157 1.28 (0.79–2.08) 5 0.004
Fixed effects 1.25 (1.06–1.46) 5 1.20 (1.06–1.36) 5
Stratified and sensitivity analyses
 Definition of subclinical 
hypothyroidism
  Exclusion of recipients of 
thyroxine
1.10 (0.81–1.50) 4 0.60 1.11 (0.60–2.05) 4 0.151
Measurement of FT4 level and normal 
FT4 level
1.28 (0.63–2.62) 3 0.79 1.20 (0.39–3.64) 3 0.171
 Stratified by sex†
  Women 1.29 (0.75–2.21) 4 0.078 1.38 (0.80–2.39) 4 0.015
  Men 1.31 (0.44-3.94) 4 0.017 0.98 (0.43–2.24) 4 0.165
 Stratified by mean age at enrollment 
in the cohorts‡
  <65 y 1.32 (0.06–28.04) 2 0.013 1.49 (0.54–4.10) 3 0.001
  ≥65 y 1.28 (0.63–2.62) 3 0.79 0.94 (0.05–17.24) 2 0.85
 Characteristics of study quality
  Formal fracture adjudication 
procedures and adjudication
  without knowledge of thyroid 
status
1.08 (0.68–1.73) 3 0.57 1.04 (0.76–1.42) 3 0.88
 Studies excluded
  HUNT2 (36), included only hip 
and forearm
   fractures as nonspine fractures
1.49 (1.03–2.14) 4 0.58 1.40 (0.73–2.68) 4 0.080
TEARS (14), included only recipients 
of thyroxine
1.12 (0.83–1.51) 4 0.69 1.10 (0.73–1.66) 4 0.27
FT4 = free thyroxine; HUNT2 = Nord Trøndelag Health Study 2; HR = hazard ratio; TEARS = Thyroid Epidemiology Audit and Research Study.
*
P > 0.10; ratios are homogeneous.
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† P for interaction (sex) = 0.98 (hip fractures) and 0.50 (nonspine fractures).
‡ P for interaction (age) = 0.98 (hip fractures) and 0.77 (nonspine fractures).
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